The latest biologic for psoriasis – bimekizumab – provides more rapid and complete clearance of symptoms than current mAbs through a novel dual action inhibiting IL-17A and IL-17F, two studies suggest. The drug has the potential to become the drug of choice for more resistant psoriasis, although there are still questions about its adverse effects ...
Psoriasis
Dual IL-17A and IL-17F inhibitor provides complete skin clearance in psoriasis
By Michael Woodhead
10 Feb 2021